论文部分内容阅读
放线菌素类是抗肿瘤抗菌素中之一族药物,其中放线菌素 D 对绒癌的治愈率超过50%,对原发Wilm 氏瘤早期,结合外科手术和放射治疗,治愈率达80%左右;对何杰金氏及非何杰金氏淋巴肉瘤,睾丸肿瘤和某些肉瘤也有疗效。临床应用虽近20年,但未见临床药理报导。本文则为第一篇关于放线菌素 D 在病人体内的药物动力学研究的报导。应用标记放线菌素 D 于三例播散性恶性黑色素瘤患者,研究其分布、排泄及代谢情况,氚标记于放线菌素 D 色
Actinomycin is a family of anti-tumor antibiotics, which actinomycin D on choriocarcinoma cure rate of more than 50%, early Wilm’s tumor, combined with surgical and radiotherapy, the cure rate of 80% ; About Hodgkin’s and non-Hodgkin’s lymphosarcoma, testicular tumors and some sarcomas are also effective. Although nearly 20 years of clinical application, but no clinical pharmacology reported. This article is the first to report on the pharmacokinetics of actinomycin D in patients. Application of labeled actinomycin D in three cases of disseminated malignant melanoma patients to study the distribution, excretion and metabolism, tritium labeled actinomycin D